Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2017 Filed Feb 9, 2017 00:38 UTC |
SHERWIN STEPHEN ADirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-17-008908 · doc4.xml · derivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:38 UTC |
SHERWIN STEPHEN ADirector
|
Tax withholdingCommon Stock | 1,169 | $43.60 | $50,968.40 |
DisclosureSEC source: 0001209191-17-008908 · doc4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,879 F1 · balance_after: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the February 7, 2017 market close price ($43.60), and this net amount ($40.20) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,831 shares to the optionee. The 1,169 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:38 UTC |
SHERWIN STEPHEN ADirector
|
Exercise / conversionCommon Stock | 15,000 | $3.40 | $51,000.00 |
DisclosureSEC source: 0001209191-17-008908 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the February 7, 2017 market close price ($43.60), and this net amount ($40.20) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,831 shares to the optionee. The 1,169 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:40 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 132 | $44.65 | $5,893.80 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222 F1 · kind: Sale of 821 and 132 shares of common stock issued upon vesting of 2175 restricted stock units to cover withholding taxes with the balance of the shares (1222) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:39 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 132 | $44.62 | $5,889.84 |
DisclosureSEC source: 0001209191-17-008910 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222 F1 · kind: Sale of 821 and 132 shares of common stock issued upon vesting of 2,175 restricted stock units to cover withholding taxes with the balance of the shares (1,222) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:44 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantRestricted Stock Option · Derivative | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008917 · doc4.xml · derivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Underlying: Common Stock · 6,100 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:44 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantStock Option · Derivative | 51,600 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008917 · doc4.xml · derivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,600 Underlying: Common Stock · 51,600 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:44 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 727 | $43.13 | $31,355.51 |
DisclosureSEC source: 0001209191-17-008917 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,756 F1 · kind: Sale of 727 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1198) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:43 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantRestricted Stock Option · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008916 · doc4.xml · derivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:43 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantStock Option · Derivative | 76,800 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008916 · doc4.xml · derivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:43 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 963 | $43.14 | $41,543.82 |
DisclosureSEC source: 0001209191-17-008916 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,666 F1 · kind: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.65 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC |
Gano KyleChief Business Development Off
|
GrantRestricted Stock Option · Derivative | 7,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008915 · doc4.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC |
Gano KyleChief Business Development Off
|
GrantStock Option · Derivative | 60,000 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008915 · doc4.xml · derivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 727 | $43.15 | $31,370.05 |
DisclosureSEC source: 0001209191-17-008915 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,311 F1 · kind: Sale of 727 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1198) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:42 UTC |
Gros David-Alexandre CPresident & COO
|
GrantRestricted Stock Option · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008914 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F2 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:41 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantRestricted Stock Option · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008913 · doc4.xml · derivative · entry 4 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:41 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantStock Option · Derivative | 76,800 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008913 · doc4.xml · derivative · entry 3 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:41 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 727 | $43.15 | $31,370.05 |
DisclosureSEC source: 0001209191-17-008913 · doc4.xml · nonDerivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Sale of 727 and 116 shares of common stock issued upon vesting of 1925 restricted stock units to cover withholding taxes with the balance of the shares (1082) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC |
OBrien Christopher FlintChief Medical Officer
|
GrantRestricted Stock Option · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008912 · doc4.xml · derivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC |
OBrien Christopher FlintChief Medical Officer
|
GrantStock Option · Derivative | 76,800 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008912 · doc4.xml · derivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 1,206 | $43.17 | $52,063.02 |
DisclosureSEC source: 0001209191-17-008912 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,038 F1 · kind: Sale of 1206 shares of common stock issued upon vesting of 3200 restricted stock units to cover withholding taxes with the balance of the shares (1994) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.46. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Option · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · derivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 76,800 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 821 | $43.11 | $35,393.31 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Sale of 821 and 132 shares of common stock issued upon vesting of 2175 restricted stock units to cover withholding taxes with the balance of the shares (1222) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:39 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Option · Derivative | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008910 · doc4.xml · derivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:39 UTC |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 68,400 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008910 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,400 Underlying: Common Stock · 68,400 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:39 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 821 | $43.13 | $35,409.73 |
DisclosureSEC source: 0001209191-17-008910 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Sale of 821 and 132 shares of common stock issued upon vesting of 2,175 restricted stock units to cover withholding taxes with the balance of the shares (1,222) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:37 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantRestricted Stock Option · Derivative | 33,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008907 · doc4.xml · derivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,400 Underlying: Common Stock · 33,400 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:37 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 207,400 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008907 · doc4.xml · derivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,400 Underlying: Common Stock · 207,400 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:37 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,010 | $43.18 | $129,971.80 |
DisclosureSEC source: 0001209191-17-008907 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,542 F1 · kind: Sale of 3010 shares of common stock issued upon vesting of 5750 restricted stock units to cover withholding taxes with the balance of the shares (2740) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.75 to $43.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:39 UTC |
Coughlin TimothyChief Financial Officer
|
SaleCommon Stock | 963 | $43.14 | $41,543.82 |
DisclosureSEC source: 0001209191-17-008909 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,961 F1 · kind: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:17 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,375 | $42.56 | $58,520.00 |
DisclosureSEC source: 0001209191-17-008133 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,558 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:19 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,375 | $42.57 | $58,533.75 |
DisclosureSEC source: 0001209191-17-008137 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,079 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:19 UTC |
Coughlin TimothyChief Financial Officer
|
SaleCommon Stock | 1,500 | $42.55 | $63,825.00 |
DisclosureSEC source: 0001209191-17-008136 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,324 F1 · kind: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:18 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,375 | $42.57 | $58,533.75 |
DisclosureSEC source: 0001209191-17-008135 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,113 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:18 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,125 | $42.55 | $132,968.75 |
DisclosureSEC source: 0001209191-17-008134 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,802 F1 · kind: Sale of 3,125 shares of common stock issued upon vesting of 6,250 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (3,125) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:16 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 1,500 | $42.50 | $63,750.00 |
DisclosureSEC source: 0001209191-17-008131 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,044 F1 · kind: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 00:29 UTC |
RASTETTER WILLIAM HDirector
|
Exercise / conversionStock Option · Derivative | 25,000 | $2.17 Strike: $2.17 | $54,250.00 |
DisclosureSEC source: 0001209191-17-007327 · doc4.xml · derivative · entry 3 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2017-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted February 4, 2010 and vested in 12 equal monthly installments beginning March 4, 2010. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 00:29 UTC |
RASTETTER WILLIAM HDirector
|
SaleCommon Stock | 10,750 | $42.28 | $454,510.00 |
DisclosureSEC source: 0001209191-17-007327 · doc4.xml · nonDerivative · entry 2 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 F1 · kind: The transaction reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.27 to $42.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 00:29 UTC |
RASTETTER WILLIAM HDirector
|
Exercise / conversionCommon Stock | 25,000 | $2.17 | $54,250.00 |
DisclosureSEC source: 0001209191-17-007327 · doc4.xml · nonDerivative · entry 1 RASTETTER WILLIAM H · CIK 0001205903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 00:29 UTC |
Gros David-Alexandre CPresident & COO
|
GrantStock Option · Derivative | 350,000 | $0.00 Strike: $42.55 | $0.00 |
DisclosureSEC source: 0001209191-17-007325 · doc4.xml · derivative · entry 1 Gros David-Alexandre C · CIK 0001644489 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on February 2, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:44 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,625 | $40.65 | $66,056.25 |
DisclosureSEC source: 0001209191-17-004304 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,738 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.98 to $41.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:45 UTC |
Coughlin TimothyChief Financial Officer
|
SaleCommon Stock | 1,750 | $40.65 | $71,137.50 |
DisclosureSEC source: 0001209191-17-004305 · doc4.xml · nonDerivative · entry 1 Coughlin Timothy P · CIK 0001376043 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,824 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.91 to $41.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:45 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,625 | $40.63 | $66,023.75 |
DisclosureSEC source: 0001209191-17-004306 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,704 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.90 to $41.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:43 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,750 | $40.65 | $152,437.50 |
DisclosureSEC source: 0001209191-17-004303 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,677 F1 · kind: Sale of 3,750 shares of common stock issued upon vesting of 7,500 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (3,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.97 to $41.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:41 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,625 | $40.63 | $66,023.75 |
DisclosureSEC source: 0001209191-17-004302 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,183 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.90 to $41.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:41 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 1,750 | $40.66 | $71,155.00 |
DisclosureSEC source: 0001209191-17-004301 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,544 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.91 to $41.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:02 UTC |
OBrien Christopher FlintChief Medical Officer
|
SaleCommon Stock | 1,750 | $43.35 | $75,862.50 |
DisclosureSEC source: 0001209191-17-003588 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,794 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.50 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:02 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,625 | $43.39 | $70,508.75 |
DisclosureSEC source: 0001209191-17-003587 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,558 F1 · kind: Sale of 1,625 shares of common stock issued upon vesting of 3,250 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,625) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.50 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:01 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,750 | $43.28 | $162,300.00 |
DisclosureSEC source: 0001209191-17-003586 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,927 F1 · kind: Sale of 3,750 shares of common stock issued upon vesting of 7,500 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (3,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.50 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.